Advertisement
Screener

PULMATRIX, INC. (PULM) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

PULMATRIX, INC. Financing Cash Flow

PULMATRIX, INC. (PULM) reported Financing Cash Flow of $950.00 thousand for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-09-17.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-09-17

  • PULMATRIX, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$50.00K.
  • PULMATRIX, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $1.00M.
  • PULMATRIX, INC. net cash provided by (used in) financing activities for the quarter ending 2023-12-31 was $0.00.
  • PULMATRIX, INC. net cash provided by (used in) financing activities for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
  • PULMATRIX, INC. net cash provided by (used in) financing activities for fiscal 2023 was $53.00K, a 95.69% decline from fiscal 2022.
  • PULMATRIX, INC. net cash provided by (used in) financing activities for fiscal 2022 was $1.23M, a 97.17% decline from fiscal 2021.
  • PULMATRIX, INC. net cash provided by (used in) financing activities for fiscal 2021 was $43.48M, a 107.21% increase from fiscal 2020.
  • PULMATRIX, INC. net cash provided by (used in) financing activities for fiscal 2020 was $20.98M, a 18.50% increase from fiscal 2019.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 12 month
2026-06-30-$50.00K
derived: S-4/A 6 month − S-4/A 3 month · filed 2026-09-17
$950.00K
S-4/A · filed 2026-09-17
2026-03-31$1.00M
S-4/A · filed 2026-08-03
2023-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21
$0.00
derived: sum of 2 quarters · filed 2025-03-21
$0.00
derived: sum of 3 quarters · filed 2025-03-21
$53.00K
10-K · filed 2025-03-21
2023-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08
$0.00
derived: sum of 2 quarters · filed 2024-11-08
$53.00K
10-Q · filed 2024-11-08
$53.00K
derived: sum of 4 quarters · filed 2024-11-08
2023-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
$53.00K
10-Q · filed 2024-08-13
$53.00K
derived: sum of 3 quarters · filed 2024-08-13
$1.44M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31$53.00K
10-Q · filed 2024-05-10
$53.00K
derived: sum of 2 quarters · filed 2024-05-10
$1.44M
derived: sum of 3 quarters · filed 2024-05-10
$1.44M
derived: sum of 4 quarters · filed 2024-05-10
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28
$1.38M
derived: sum of 2 quarters · filed 2024-03-28
$1.38M
derived: sum of 3 quarters · filed 2024-03-28
$1.23M
10-K · filed 2024-03-28
2022-09-30$1.38M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$1.38M
derived: sum of 2 quarters · filed 2023-11-09
$1.23M
10-Q · filed 2023-11-09
$7.42M
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
-$152.00K
10-Q · filed 2023-08-10
$6.04M
derived: sum of 3 quarters · filed 2023-08-10
$6.04M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31-$152.00K
10-Q · filed 2023-05-12
$6.04M
derived: sum of 2 quarters · filed 2023-05-12
$6.04M
derived: sum of 3 quarters · filed 2023-05-12
$6.04M
derived: sum of 4 quarters · filed 2023-05-12
2021-12-31$6.19M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30
$6.19M
derived: sum of 2 quarters · filed 2023-03-30
$6.19M
derived: sum of 3 quarters · filed 2023-03-30
$43.48M
10-K · filed 2023-03-30
2021-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
$0.00
derived: sum of 2 quarters · filed 2022-11-10
$37.28M
10-Q · filed 2022-11-10
$37.28M
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10
$37.28M
10-Q · filed 2022-08-10
$37.28M
derived: sum of 3 quarters · filed 2022-08-10
$50.15M
derived: sum of 4 quarters · filed 2022-08-10
2021-03-31$37.28M
10-Q · filed 2022-05-12
$37.28M
derived: sum of 2 quarters · filed 2022-05-12
$50.15M
derived: sum of 3 quarters · filed 2022-05-12
$58.00M
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29
$12.87M
derived: sum of 2 quarters · filed 2022-03-29
$20.72M
derived: sum of 3 quarters · filed 2022-03-29
$20.98M
10-K · filed 2022-03-29
2020-09-30$12.87M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10
$20.72M
derived: sum of 2 quarters · filed 2021-11-10
$20.98M
10-Q · filed 2021-11-10
$20.98M
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30$7.85M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10
$8.11M
10-Q · filed 2021-08-10
$8.12M
derived: sum of 3 quarters · filed 2021-08-10
$8.12M
derived: sum of 4 quarters · filed 2021-08-10
2020-03-31$260.00K
10-Q · filed 2021-05-11
$263.00K
derived: sum of 2 quarters · filed 2021-05-11
$267.00K
derived: sum of 3 quarters · filed 2021-05-11
$14.92M
derived: sum of 4 quarters · filed 2021-05-11
2019-12-31$3.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23
$7.00K
derived: sum of 2 quarters · filed 2021-03-23
$14.66M
derived: sum of 3 quarters · filed 2021-03-23
$17.70M
10-K · filed 2021-03-23
2019-09-30$4.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12
$14.65M
derived: sum of 2 quarters · filed 2020-11-12
$17.70M
10-Q · filed 2020-11-12
$20.64M
derived: sum of 4 quarters · filed 2020-11-12
2019-06-30$14.65M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07
$17.70M
10-Q · filed 2020-08-07
$20.63M
derived: sum of 3 quarters · filed 2020-08-07
$20.62M
derived: sum of 4 quarters · filed 2020-08-07
2019-03-31$3.05M
10-Q · filed 2020-05-14
$5.98M
derived: sum of 2 quarters · filed 2020-05-14
$5.97M
derived: sum of 3 quarters · filed 2020-05-14
$17.71M
derived: sum of 4 quarters · filed 2020-05-14
2018-12-31$2.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26
$2.92M
derived: sum of 2 quarters · filed 2020-03-26
$14.66M
derived: sum of 3 quarters · filed 2020-03-26
$15.79M
10-K · filed 2020-03-26
2018-09-30-$8.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-01
$11.73M
derived: sum of 2 quarters · filed 2019-11-01
$12.86M
10-Q · filed 2019-11-01
$13.30M
derived: sum of 4 quarters · filed 2019-11-01
2018-06-30$11.74M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05
$12.87M
10-Q · filed 2019-08-05
$13.31M
derived: sum of 3 quarters · filed 2019-08-05
$13.33M
derived: sum of 4 quarters · filed 2019-08-05
2018-03-31$1.13M
10-Q · filed 2019-05-15
$1.57M
derived: sum of 2 quarters · filed 2019-05-15
$1.59M
derived: sum of 3 quarters · filed 2019-05-15
2017-12-31$440.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19
$463.00K
derived: sum of 2 quarters · filed 2019-02-19
$13.92M
10-K · filed 2019-02-19
2017-09-30$23.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14
$13.48M
10-Q · filed 2018-11-14
2017-06-30$13.46M
10-Q · filed 2018-08-03

Similar stocks

Stock NameCountryMarket CapPE Ratio
Ernexa Therapeutics Inc. (ERNA)United States$0.006B
ProPhase Labs, Inc. (PRPH)United States$0.006B-0.06
Xenetic Biosciences, Inc. (XBIO)United States$0.006B
Enveric Biosciences, Inc. (ENVB)United States$0.007B-0.63
Bolt Biotherapeutics, Inc. (BOLT)United States$0.007B-0.26
SYNLOGIC, INC. (SYBX)United States$0.007B
Processa Pharmaceuticals, Inc. (PCSA)United States$0.005B
Acurx Pharmaceuticals, Inc. (ACXP)United States$0.007B-0.97
AMARIN CORP PLC\UK (AMRN)$0.005B-247.24
CNS Pharmaceuticals, Inc. (CNSP)United States$0.007B